Medical Technology

@xconomy.com 3 years ago

Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin

@xconomy.com 3 years ago

Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later

@xconomy.com 4 years ago

HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic

@xconomy.com 4 years ago

Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs

@xconomy.com 4 years ago

Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More

@xconomy.com 4 years ago

Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic

@xconomy.com 4 years ago

Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B

@xconomy.com 4 years ago

Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further

@xconomy.com 5 years ago

MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms

@xconomy.com 5 years ago

Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline

@xconomy.com 5 years ago

With OneOncology, Flatiron and Cancer Docs Aim to Boost Community Care

@xconomy.com 5 years ago

With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?

@xconomy.com 5 years ago

With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines

@xconomy.com 6 years ago

Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines